Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27795601 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL5493689 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL1008410 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL2732833 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL7411764 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL9436412 | 0.98 | PRKCA (0.62) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL4324597 | 0.93 | PRKCA (0.59) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL4912502 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL4912512 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL1000470 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599572-B2 | Solid lipid nanoparticles of curcumin | Punjab University Chandigarh (IN) | 2026-04-14 | — | — | US | claimed |
| US-20220151945-A1 | SOLID LIPID NANOPARTICLES OF CURCUMIN | REGISTRAR, PANJAB UNIVERSITY CHANDIGARH (IN) | 2022-05-19 | — | — | US | claimed |
| US-9907758-B2 | Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins | PANJAB UNIVERSITY DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2018-03-06 | — | — | US | claimed |
| US-20140348938-A1 | PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2014-11-27 | — | — | US | claimed |
| WO-2013105026-A1 | A PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | DEPARTMENT OF BIOTECHNOLOGY (DBT) (IN) | 2013-07-18 | — | — | WO | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12599572-B2 | Solid lipid nanoparticles of curcumin | Punjab University Chandigarh (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20260076897-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260021042-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260007594-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12414916-B2 | Dry powder formulations of epinephrine and associated methods | Belhaven BioPharma Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250000792-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | Belhaven BioPharma Inc. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-2268272-A2 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | Mount Sinai School of Medicine of New York University (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2210590-A1 | Drug delivery system for use in the treatment of vascular and vessel-related pathologies | Academisch Medisch Centrum (NL) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009136979-A2 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| EP-0784430-B1 | METHOD FOR REDUCING UNWANTED CELLULAR ADHESIONS | PHANOS TECH INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-5480901-A | CONJUGATE OF LIPOPHILIC BINDING AGENT AND DRUG, QUATERNARY AMMONIUM COMPOUND, CONTROLLING TUMOR FORMATION | ZYNAXIS, INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-4725588-A | Alkyl phospholipid antihypertensive agents in method of lowering blood pressure | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1988-02-16 | — | — | US | disclosed |
| US-4595681-A | Administering neutral glycerolipid | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151945-A1 | SOLID LIPID NANOPARTICLES OF CURCUMIN | PLIN1, LIPC, NPC1L1 | PRKCA 1368/4885USP2 191/4885ADRA1D 4431/4885 |
| US-20260007594-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | ADRA1D, ADRB2, ADRB3 | PRKCA 1005/4885USP2 3366/4885ADRA1D 1/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | PRKCA 779/4885USP2 3686/4885ADRA1D 11/4885 |
| US-20260021042-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | ADRB2, ADRA1D, ADRA2C | PRKCA 2590/4885USP2 3171/4885ADRA1D 2/4885 |
| US-20140348938-A1 | PROCESS FOR PREPARING SOLID LIPID SUSTAINED RELEASE NANOPARTICLES FOR DELIVERY OF VITAMINS | VDR, RARA, STRA6 | PRKCA 1047/4885USP2 2924/4885ADRA1D 116/4885 |
| US-20260076897-A1 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | COMT, CMA1, ADRB3 | PRKCA 1673/4885USP2 1563/4885ADRA1D 7/4885 |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | PRKCA 1613/4885USP2 3125/4885ADRA1D 1551/4885 |
| US-12599572-B2 | Solid lipid nanoparticles of curcumin | CPT1A, CPT2, SCD | PRKCA 742/4885USP2 290/4885ADRA1D 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.